The role of albuminuria as a non-invasive marker for congestive acutely decompensated chronic heart failure and the spironolactone effect in elderly Portuguese: A non-randomized trial

Nephrology

Volumn 19, Issue 3, 2014, Pages 149-156

  Ferreira, João Pedro ^a   Santos, Mário ^a   Almeida, Sofia ^b   Marques, Irene ^a   Bettencourt, Paulo ^c   Carvalho, Henrique ^a  

^a Institute of Biomedical Sciences Abel Salazar   (Portugal)

^b UNIVERSITY OF LISBON   (Portugal)

^c Universidade do Porto   (Portugal)

Author keywords

acute heart failure; acute kidney injury; albuminuria

Indexed keywords

BIOLOGICAL MARKER; SPIRONOLACTONE;

AGED; ALBUMINURIA; CLINICAL TRIAL; COMPARATIVE STUDY; FEMALE; HEART FAILURE; HUMAN; MALE; PROSPECTIVE STUDY; URINE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALBUMINURIA; BIOLOGICAL MARKERS; FEMALE; HEART FAILURE; HUMANS; MALE; PROSPECTIVE STUDIES; SPIRONOLACTONE;

EID: 84894232853     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12188     Document Type: Article

References (38)

1. Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421-426. (Pubitemid 32681484)
2. Mansia G, De Backer G, Dominiczak A, et al. ESH-ESC guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press. 2007; 16: 135-232.
3. Standards of medical care in diabetes-2013. Diabetes Care 2013; 36 (Suppl 1): S11-66.
4. Jackson CE, Solomon SD, Gerstein HC, et al. Albuminuria in chronic heart failure: Prevalence and prognostic importance. Lancet 2009; 374: 543-550.
5. Chugh A, Bakris GL,. Microalbuminuria: What is it? Why is it important? What should be done about it? An update. J. Clin. Hypertens. 2007; 9: 196-200.
6. Weir MR,. Microalbuminuria and cardiovascular disease. Clin. J. Am. Soc. Nephrol. 2007; 2: 581-590.
7. van de Wal RM, Asselbergs FW, Plokker HW, et al. High prevalence of microalbuminuria in chronic heart failure patients. J. Card. Fail. 2005; 11: 602-606. (Pubitemid 41463731)
8. Koyama S, Sato Y, Tanada Y, Fujiwara H, Takatsu Y,. Early evolution and correlates of urine albumin excretion in patients presenting with acutely decompensated heart failure. Circ. Heart Fail. 2013; 6: 227-232.
9. Schrier RW, Abraham WT,. Hormones and hemodynamics in heart failure. N. Engl. J. Med. 1999; 341: 577-585. (Pubitemid 29384167)
10. Schrier RW,. Role of diminished renal function in cardiovascular mortality: Marker or pathogenetic factor? J. Am. Coll. Cardiol. 2006; 47: 1-8. (Pubitemid 43005157)
11. Gekle M, Grossmann C,. Actions of aldosterone in the cardiovascular system: The good, the bad, and the ugly? Pflugers Arch. 2009; 458: 231-246.
12. Marney AM, Brown NJ,. Aldosterone and end-organ damage. Clin. Sci. (Lond.) 2007; 113: 267-278. (Pubitemid 47372685)
13. Albaghdadi M, Gheorghiade M, Pitt B,. Mineralocorticoid receptor antagonism: Therapeutic potential in acute heart failure syndromes. Eur. Heart J. 2011; 32: 2626-2633.
14. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 2009; 150: 604-612.
15. Masson S, Latini R, Milani V, et al. Prevalence and prognostic value of elevated urinary albumin excretion in patients with chronic heart failure: Data from the GISSI-Heart Failure trial. Circ. Heart Fail. 2010; 3: 65-72.
16. Capes SE, Gerstein HC, Negassa A, Yusuf S,. Enalapril prevents clinical proteinuria in diabetic patients with low ejection fraction. Diabetes Care 2000; 23: 377-380. (Pubitemid 30131748)
17. Blecker S, Matsushita K, Kottgen A, et al. High-normal albuminuria and risk of heart failure in the community. Am. J. Kidney Dis. 2011; 58: 47-55.
18. Ardaillou R, Chansel D,. Glomerular effects of angiotensin II: A reappraisal based on studies with non-peptide receptor antagonists. J. Hypertens. Suppl. 1993; 11: S43-47. (Pubitemid 23120561)
19. Denton KM, Anderson WP, Sinniah R,. Effects of angiotensin II on regional afferent and efferent arteriole dimensions and the glomerular pole. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2000; 279: R629-638.
20. Yoshioka T, Mitarai T, Kon V, Deen WM, Rennke HG, Ichikawa I,. Role for angiotensin II in an overt functional proteinuria. Kidney Int. 1986; 30: 538-545. (Pubitemid 17171338)
21. Amann K, Rump LC, Simonaviciene A, et al. Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J. Am. Soc. Nephrol. 2000; 11: 1469-1478. (Pubitemid 30483463)
22. Bakris GL, Fonseca V, Katholi RE, et al. Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. Hypertension 2005; 46: 1309-1315. (Pubitemid 43189728)
23. Swedberg K, Kjekshus J,. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). Am. J. Cardiol. 1988; 62: 60A-66.
24. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N. Engl. J. Med. 1991; 325: 293-302.
25. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N. Engl. J. Med. 1996; 334: 1349-1355. (Pubitemid 26152713)
26. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 1999; 353: 9-13.
27. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-2007.
28. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 1999; 341: 709-717. (Pubitemid 29407370)
29. Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF,. Aldosterone antagonists for preventing the progression of chronic kidney disease: A systematic review and meta-analysis. Clin. J. Am. Soc. Nephrol. 2009; 4: 542-551.
30. Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: A randomized, double-blind trial. Eur. Heart J. 2013; 34: 2453-2463.
31. Doty JM, Saggi BH, Sugerman HJ, et al. Effect of increased renal venous pressure on renal function. J. Trauma 1999; 47: 1000-1003. (Pubitemid 30007551)
32. Maxwell MH, Breed ES, Schwartz IL,. Renal venous pressure in chronic congestive heart failure. J. Clin. Invest. 1950; 29: 342-348.
33. Blake WD, Wegria R, et al. Effect of increased renal venous pressure on renal function. Am. J. Physiol. 1949; 157: 1-13.
34. Berton G, Cordiano R, Palmieri R, Cucchini F, De Toni R, Palatini P,. Microalbuminuria during acute myocardial infarction; a strong predictor for 1-year mortality. Eur. Heart J. 2001; 22: 1466-1475. (Pubitemid 32769174)
35. Damman K, van Deursen VM, Navis G, Voors AA, van Veldhuisen DJ, Hillege HL,. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J. Am. Coll. Cardiol. 2009; 53: 582-588.
36. Jessup M, Costanzo MR,. The cardiorenal syndrome: Do we need a change of strategy or a change of tactics? J. Am. Coll. Cardiol. 2009; 53: 597-599.
37. Wegria R, Capeci NE, Blumenthal MR, et al. The pathogenesis of proteinuria in the acutely congested kidney. J. Clin. Invest. 1955; 34: 737-743.
38. Ferreira JP, Santos M, Almeida S, Marques I, Bettencourt P, Carvalho H,. Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure. Eur. J. Intern. Med. 2013; doi: 10.1016/j.ejim.2013.08.711 [Epub ahead of print]